Biomarker Type: Proteomic
-
Generation of high quality MALDI-TOF serum mass spectra to detect hepatocellular carcinoma in high-risk patients
-
Costs and Outcomes Comparison of Tissue and Blood Based Biopsies for the Purpose of Biomarker Testing for Advanced Non-Small Cell Lung Cancer
-
A mass spectrometry-based serum test to predict outcome of treatment with nivolumab: Analysis of samples taken during therapy
-
Continuing Development of BDX003 a Serum-based MALDI-TOF Test to Detect Hepatocellular Carcinoma in High-risk Patients
-
Hypothesis independent test development using mass spectrometry data from patient clinical groups reveals underlying biological pathways
-
Pre-treatment patient selection for nivolumab benefit based on serum mass spectra
-
Comparative assessment of MALDI-TOF platforms for utility in CDx development of a proteomic signature for ficlatuzumab
-
Outcome and economic implications of proteomic test-guided second- or third-line treatment for advanced non-small cell lung cancer: Extended analysis of the PROSE trial
-
A mass spectrometry based serum test for the detection of hepatocellular carcinoma (HCC) in high risk patients
-
A mass spectrometry-based serum protein test for prognosis of patients with MDS